Articles

71. The Environmental Impact of Clinical Trials 8/8/2013

    For many years it has been almost universally accepted that there are various sources that may impact or cause disease among which biological, social, and environmental differences have all been investigated. Many clinical trials have been conducted to assess the impact of the environment on outcomes e.g., the effect of the environment on the outcome of studies assessing the efficacy of drugs for patients with dry-eye syndrome, the impact of diet on obesity and cardiovascular disease, and the impact of the environment on autoimmune diseases have all been studied, as have many other interactions.

72. Takeda's Approach To Becoming A Global Player In The Vaccine Market 7/31/2013

    In 2008 Takeda Pharmaceuticals took aim at becoming a global pharmaceutical company by making a number of strategic moves, such as the dissolution of the 23-year, 50/50 joint venture with Abbott, known as TAP Pharmaceuticals, and acquiring Millennium Pharmaceuticals (2008) and Nycomed. These changes strengthened Takeda’s position in two of the largest pharmaceutical markets outside of Japan (U.S. and EU), placing it on the verge of being the first Japanese company to be listed among the 10 largest pharmaceutical companies in the world. With 2012 net sales of $18.4 billion, Takeda ranks twelfth, up four spots from the previous year. What will get them to the next level?

73. Increased Demand For Vaccines Will Continue To Benefit CMOs 4/26/2013

    The demand for influenza vaccine brings time-to-market and cost of production to the forefront, and is among the top three reasons to outsource work to a CMO.

74. The New Pfizer Research Strategy: Openness And Collaboration Replace The Old Imperial Model 6/28/2012

    Pfizer’s new research strategy headed by Jose-Carlos Gutierrez-Ramos, has a mission to “entrepreneurialize” discovery and development and bring together three main forces in drug research: academia, biotechnology, and pharmaceuticals.. By Wayne Koberstein, contributing editor

75. Adding Value To The Drug Development Process 4/30/2012

    Life science companies can gain advantages from working with external partners that can bridge the divide between drug development and commercialization. By William Crown, Ph.D.

76. Kemwell Overview 3/29/2012
    Manufacturing customers include top pharmaceutical companies – Allergan, Bayer, GSK, J&J, Pfizer, Teva, and Novartis, as well as small emerging biotech.
77. Kemwell Biopharma Brochure 3/29/2012
    Kemwell Biopharma will offer services ranging from full-service process development, manufacture, formulation and fill and finish at the cGMP manufacturing facility in Bangalore, India as a one-stop-shop through access to Boehringer Ingelheim's® cell line development with the BI HEX technology platform, followed by a preferred access to the large-scale commercial production of Boehringer Ingelheim at its facilities in Europe.
78. Sterile Clinical Trial Material Formulation & Filling 3/26/2012
    DSM offers sterile clinical trial formulation and filling that meets the unique needs of global pharmaceutical and biotech customers.
79. Cytotoxic Formulation & Filling 3/26/2012
    DSM expanded their commercial-scale sterile pharmaceutical services by offering filling and lyophilization of cytotoxic products.
80. Clinical Trial Approval Process In Brazil - Clearing The Roadblocks To International Studies 3/22/2012

    The regulation of clinical research in Brazil started at the national level in 1996 with the publication of Resolution 196 from the National Health Council (CNS, which is a Portuguese acronym). By John Andrews and Eduardo Pizolato